Trial Profile
Safety and Immunogenicity of a Booster Dose of the Recombinant Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults After Primary Immunization
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Ad5 EBOV DNA vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacodynamics
- 13 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2015 New trial record